Morgan Stanley upgraded Novartis (NVS) to Overweight from Equal Weight with a price target of CHF 110, up from CHF 108. The firm cites valuation for the upgrade following the recent shared selloff. Novartis is underdoing an improving portfolio mix into the upcoming Rhapsido launch, the analyst tells investors in a research note. Morgan Stanley expects the company’s 2026 growth to be modest, but anticipates an acceleration from 2027.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Positive Long-Term Growth Outlook for Novartis AG Amid Temporary Setbacks
- FDA moves to accelerate biosimilar development, lower drug costs
- Novartis reports NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective
- Novartis AG Reports Strong Q3 2025 Earnings Growth
- Novartis AG Earnings Call: Growth Amid Challenges